#
Fylnetra
  • Professionals
  • FDA PI

Fylnetra

Generic name:pegfilgrastim
Dosage form: injection
Drug class:Colony stimulating factors

Medically reviewed by Drugs.com. Last updated on May 1, 2022.

Indications and Usage for Fylnetra

Patients with Cancer Receiving Myelosuppressive Chemotherapy

Fylnetra is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14.1)].

Limitations of Use

Fylnetra is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Fylnetra Dosage and Administration

Patients with Cancer Receiving Myelosuppressive Chemotherapy

The recommended dosage of Fylnetra is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Do not administer Fylnetra between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

Administration

Fylnetra is administered subcutaneously via a single-dose prefilled syringe for manual use.

Prior to use‚ remove the carton from the refrigerator and allow the Fylnetra prefilled syringe to reach room temperature for a minimum of 30 minutes. Discard any prefilled syringe left at room temperature for greater than 72 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Fylnetra if discoloration or particulates are observed.

The needle cap on the prefilled syringe is not made with natural rubber latex.

LEARN MORE ABOUT US
CONTACT INFORMATION

LINKS

MEDICAL DEPARTMENTS

Cardiology
Pediatrics
Diabetes Care
Pre-natal Care
Ultrasound Echocardiogram